Skip to content

Author

X. Le

We have 5 of 73 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD.

BACKGROUND ORCHARD (NCT03944772) was a biomarker-directed, phase II, platform study conducted to characterize resistance mechanisms and evaluate novel treatment combinations in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) following progression on first-line osimertini...

J. Goldman, J. W. Riess, Byoung Chul Cho et al. · 0 citations
Review Sep 2026

P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.

PURPOSE A structure-function classification has defined epidermal growth factor receptor (EGFR) P-loop/αC-helix compressing (PACC) mutations and exon 20 insertions (ex20ins) as distinct subsets of kinase domain EGFR alterations. Lung cancers harboring those mutations display reduced sensitivity to EGFR tyrosine kinase...

F. Monaca, I. Randulfe, J. Heymach et al. · 0 citations
Clinical trial Sep 2026

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

This study aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC whose disease progressed after third-generation EGFR tyrosine kinase inhibitor (TKI) therapy.

X. Le, A. Passaro, Yuan-Yuan Zhao et al. · 0 citations
Review Aug 2026

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

Findings support sutetinib as a potential treatment option for this molecularly heterogeneous population of adults with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations and demonstrate clinically meaningful antitumor activity with a manageable safety profile.

Feng-Ying Wu, Wei Zhang, Yan-Qiu Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.